TIDMTSTL

Tristel PLC

27 February 2017

Tristel plc

("Tristel" or the "Company")

Fuse for Stella products approved by Australia's Therapeutic Goods Association

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that its Fuse disinfectant used in its Stella decontamination tray has been approved as a high-level disinfectant by Australia's Therapeutic Goods Association ("TGA").

Stella and Fuse are specifically designed for the decontamination of small single-channelled instruments, with a particular focus on urology. Flexible cystoscopes are used by urologists for urethral, bladder and kidney examinations and Stella is targeted at this instrument. However, it can also be used to decontaminate bronchoscopes used in respiratory medicine, laryngoscopes used in anaesthesia, manometry catheters used in GI physiology, transoesophageal echo probes used in cardiology, and nasendoscopes used in hospital ear, nose and throat clinics.

First introduced to the global hospital market in 2011, 600 Stella systems have been sold worldwide and Fuse and Stella registered GBP1 million sales for the Company during its last financial year.

Stella is a plastic tray sculptured to accommodate cystoscopes whilst occupying minimal work-top space. It is battery-powered, requiring no connection to hospital services and is service / maintenance free. It is the world's only plug and play decontamination concept. Stella achieves all the outcomes of automated endoscope washers at a fraction of their cost and with none of their complexity and operational unreliability. Fuse delivers Tristel's high-level disinfectant into the Stella tray.

Tristel has had a presence in the Australian hospital market since 2011 when it received its first approval from the TGA for its Wipes System. From 2011 to 2016 Tristel was represented in the country by a distributor, and in August Tristel purchased the distributor's business and established a direct presence in the Australian hospital market via its wholly-owned subsidiary, Tristel Pty Limited.

Paul Swinney, CEO of Tristel plc, comments: "Every regulatory approval gained is a key milestone for Tristel, but this one is particularly exciting. Australia has been a very successful and profitable market for us, and the acquisition of our distributor's business in August 2016 has surpassed expectations. Since the acquisition, we have gained approvals for our Fuse for Surfaces, Jet for Surfaces and Rinse Assure products, and now we have Fuse for Stella to add to the portfolio our team can sell. Australia is a hospital market that has a real need for the Stella decontamination concept, with so many of the country's thousand or so public and private hospitals in remote locations."

For further information please contact:

 
 Tristel plc                             www.tristel.com 
 Paul Swinney, Chief Executive        Tel: 01638 721 500 
 Liz Dixon, Finance Director 
 
 finnCap 
 Geoff Nash / Giles Rolls,            Tel: 020 7220 0500 
  Corporate Finance 
 Alice Lane, Corporate Broking 
 
 Walbrook PR Ltd                   Tel: 020 7933 8780 or 
                                  tristel@walbrookpr.com 
 Paul McManus                         Mob: 07980 541 893 
 Lianne Cawthorne                     Mob: 07584 391 303

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADMGZZNVRGNZM

(END) Dow Jones Newswires

February 27, 2017 02:01 ET (07:01 GMT)

Tristel (LSE:TSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Tristel Charts.
Tristel (LSE:TSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Tristel Charts.